{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:50:16Z","timestamp":1790002216928,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jaci.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T07:52:09Z","timestamp":1724399529000},"page":"135-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-667X","authenticated-orcid":false,"given":"Lisa A.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Muraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Rodr\u00edguez Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.08.005_bib1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.08.005_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.08.005_bib3","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/all.12619","article-title":"Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities","volume":"70","author":"Mortz","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.08.005_bib4","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/all.15721","article-title":"Atopic dermatitis: correlation of distinct risk factors with age of onset in adulthood compared to childhood","volume":"78","author":"Maintz","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.08.005_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-065X.2011.01027.x","article-title":"Atopic dermatitis: a disease of altered skin barrier and immune dysregulation","volume":"242","author":"Boguniewicz","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2024.08.005_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00403-011-1198-9","article-title":"Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis","volume":"304","author":"Kou","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2024.08.005_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaci.2018.11.006","article-title":"The atopic march and atopic multimorbidity: many trajectories, many pathways","volume":"143","author":"Paller","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.08.005_bib8","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2024.08.005_bib9","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2024.08.005_bib10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.08.005_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100131","article-title":"Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis","volume":"2","author":"Beck","year":"2022","journal-title":"JID Innov"},{"key":"10.1016\/j.jaci.2024.08.005_bib12","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.08.005_bib13","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.08.005_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2024.08.005_bib15","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2024.08.005_bib16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.08.005_bib18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.08.005_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1399-3038.2009.00851.x","article-title":"Serum measurement of thymus and activation-regulated chemokine\/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis","volume":"20","author":"Fujisawa","year":"2009","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.08.005_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/pde.15245","article-title":"Elevated serum total IgE is associated with eczema exacerbation\u00a0in children hospitalized for atopic dermatitis","volume":"40","author":"Atwal","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2024.08.005_bib21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaci.2013.08.037","article-title":"New childhood and adult reference intervals for total IgE","volume":"133","author":"Martins","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.08.005_bib22","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.4049\/jimmunol.146.5.1478","article-title":"Frequency analysis of IgE-secreting B lymphocytes in persons with normal or elevated serum IgE levels","volume":"146","author":"King","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2024.08.005_bib23","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/cea.14384","article-title":"IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval","volume":"53","author":"Dekkers","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.08.005_bib25","author":"Farhana"},{"key":"10.1016\/j.jaci.2024.08.005_bib26","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jid.2018.03.1517","article-title":"Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype","volume":"138","author":"Simpson","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2024.08.005_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070295","article-title":"Investigating eosinophilia","volume":"380","author":"Thakker","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2024.08.005_bib28","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.08.005_bib29","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.08.005_bib30","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3389\/fimmu.2020.01768","article-title":"Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers","volume":"11","author":"He","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2024.08.005_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry","volume":"75","author":"Ari\u00ebns","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.08.005_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13887","article-title":"Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry","volume":"33","author":"Kamphuis","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.08.005_bib33","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events","volume":"151","author":"Geba","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924008261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924008261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:46:06Z","timestamp":1762231566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924008261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0091674924008261"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.08.005","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}